The medtech space continues to advance at an exhilarating speed, with further advances in health coming out every year. In recent years, biobanking has taken off, which is a sizable collection of biological samples that are stored primarily for use in medical and health research. According to Transparency Market Research, the global biobanking market was valued at $ 50.1 billion in 2021 and is expected to grow to over $ 87.4 billion by the end of 2031.
North America accounted for the largest share of the global bio-banking market in 2021. Increased adoption of advanced technologies and increased awareness of bio-banking has enabled the region to thrive and present more opportunities to further benefit human health.
Recently, I sat down with Salvatore Viscomithe Medical Director of GoodCell, one of the leading biobank organizations in the world. He provided insight into what to expect in the future of biobanking and how GoodCell is paving the way for further innovations that could help save lives from previously incurable conditions.
Salvatore and GoodCell will be a BIOME Boston device from September 28-29 to the Boston Convention and Exhibition Center. BIOMEDevice Boston brings together the best engineers, business leaders, disruptive companies and innovative thinkers from the best medical device start-ups and OEMs in the Northeast to inspire the next life-changing medical device. Hang in here to watch the show.
Adrienne: For those who don’t know who you are, tell us a little about yourself and how you fit into the biomedical industry.
Salvatore: I am a practicing doctor, researcher and serial entrepreneur. I currently lead the GoodCell product line of genetic testing and biomarkers, developing a health platform that harnesses the power of blood to inform and restore health. Previously, I spent 14 years as a faculty member at Harvard Medical School and simultaneously as a physician at Brigham and Women’s Hospital. In that capacity, I have held various administrative and clinical roles, including Director of Admissions for a Harvard residency program. As a medical imaging expert, I have published and presented nationally and internationally. I co-founded Brigham NightWatch, the world’s first teleradiology academic network. In addition, I was an executive member and board member of FreMon Scientific, where I led the development of a next-generation blood product management solution that was approved by the FDA and ultimately brought to market. I began my medical journey while attending Columbia University, earning a Bachelor’s degree in Neuropsychology, completing my residency and residency at Harvard Medical School. I also serve on the board of directors of the Make-A-Wish Foundation Massachusetts / Rhode Island. In 2016 I completed the Executive Education Program at Harvard Business School.
A: We are so excited to have your support as a keynote speaker at BIOMEDevice Boston. Do you have interesting news to share from GoodCell?
S: GoodCell, a life sciences company, is a preventative health care service launched earlier this year that allows people to prepare for personalized medicine opportunities by storing their biomaterial via Personal Biobanking for future potential cell therapies. .
This is an exciting time to have healthy cell storage at your fingertips thanks to the thousands of cell and gene therapies being studied to treat diseases and conditions that could impact millions of Americans. They range from neurodegenerative diseases like Parkinson’s to some cancers to major chronic conditions like heart disease and diabetes. Based on the current clinical trial pipeline, the FDA plans to approve 10-20 new cell and gene therapies per year starting in 2025.
Additionally, GoodCell is developing new genetic tests that evaluate dynamic genetic changes in our cells, rather than just the risks inherited from conventional genetic testing. Measuring specific somatic changes in the blood over time can be used to predict the risk of cardiovascular disease and certain cancers, as well as to explain why some people have abnormal inflammatory responses when infected with COVID-19.
A: What trends do you see coming and how will they be highlighted in this event?
S: I see trends toward democratization of patients in the form of personalized dashboards that integrate health information. Patients will also benefit from sophisticated home health monitoring that will replace traditional hospital care and clinical trials, leading to more effective disease screening and monitoring. Finally, I think integrating data from multiple sources will enable the creation of digital twin models to predict certain health risks and inform the development of therapies.
A: What are you most looking forward to at BIOMEDevice Boston this month?
S: I’m looking forward to seeing new devices and software solutions that address chronic diseases that have been so difficult to manage effectively in the past. In particular, innovative tools that acquire physiological and biological data to allow the best remote monitoring of patients, both for hospital home care and for decentralized clinical trials.